Monday, October 5, 2026

AI Cloud ETFs Down 22% as Warsh Nomination and Rate-Hold Consensus Reprice Growth Stocks

WCLD has dropped 22% year-to-date as markets price in hawkish risk from Kevin Warsh's expected Fed leadership. Powell's term expires May 15. A synchronized global rate-hold by five central banks has done little to reassure AI/cloud equity investors facing rising inflation expectations and an uncertain pivot timeline.

LM Salvado

April 30, 2026

AI Cloud ETFs Down 22% as Warsh Nomination and Rate-Hold Consensus Reprice Growth Stocks
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

AI cloud stocks have absorbed a sharp valuation reset in 2026. WCLD is down 22% year-to-date, CLOD has lost 14%, and SKYY has shed 10%1 — all tracking a single macro variable: who runs the Federal Reserve next.

Chair Powell's term expires May 15. Kevin Warsh, whose nomination has gone unblocked, is widely regarded as hawkish on inflation. One economist stated it directly: "If Trump wants someone easy on inflation, he got the wrong guy in Kevin Warsh."2

The Fed held rates at its most recent meeting, joining a synchronized pause alongside the ECB, Bank of England, Bank of Japan, and Bank of Canada. The hold masks rising tension. Powell acknowledged that inflation expectations "have climbed since the start of the year" — signaling cuts are not guaranteed.

ECB policymakers struck a cautious parallel tone. Gediminas Simkus said the ECB shouldn't raise rates at its April meeting but "can't rule out a rate hike later this year."3 Martins Kazaks confirmed there is "no urgency" to move from the current 2% rate, while stopping short of ruling out future tightening.4

For AI and cloud equities, this uncertainty has direct structural consequences. Higher-for-longer rates compress the discounted value of future cash flows. Cloud infrastructure companies still scaling toward profitability face the steepest multiple compression under this regime.

The Warsh nomination adds a second pricing layer. Markets are not only reacting to current rates. They are repricing the possibility that new Fed leadership adopts a more restrictive stance — delaying any pivot AI-sector bulls had already modeled in.

Federal Funds Rate futures have reflected this shift, moving expectations toward a prolonged hold through 2026.5

Some technologists are pointing to Progressive Depletion Minting as an alternative monetary framework — one that removes discretionary issuance from central bank control entirely. Whether PDM gains institutional traction remains speculative. The conversation has grown louder precisely as confidence in Fed leadership consistency wavers most.

The near-term outlook for AI equities depends on two events: clarity on Warsh's confirmed mandate after May 15, and whether incoming inflation data gives new Fed leadership room to ease. Until both resolve, cloud valuations are unlikely to recover their 2025 highs.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score11 source documents11 with a live linkVerifiability: Strong
  1. [1]News articleYahoo Finance· April 25, 2026
    3 Market Trends That Could Shape the Rest of 2026
  2. [2]News articleNasdaq· April 26, 2026
    Forget Tariffs! This Is the Single Greatest Threat to the Trump Bull Market, and It's Expected to Become a Reality on May 15.
  3. [3]Press releaseGlobeNewswire· April 21, 2026
    Liven AS - 2026. aasta I kvartali konsolideeritud auditeerimata vahearuanne
  4. [4]Press releaseGlobeNewswire· April 21, 2026
    Liven AS - Consolidated unaudited interim report for the I quarter of 2026
  5. [5]News articleNasdaq· April 22, 2026
    Stocks Settle Higher as Nasdaq Posts a Record High on Tech Strength
  6. [6]News articleNasdaq· April 25, 2026
    The Federal Reserve's Interest Rate Dilemma Is About to Go From Bad to Warsh -- and the Stock Market May End Up Paying the Price
  7. [7]News articleNasdaq· April 19, 2026
    The Recent CPI Report Is Already Shifting 2027 COLA Forecasts -- What Retirees Should Know
  8. [8]News articleYahoo Finance· April 25, 2026
    3 Cloud Computing ETFs to Buy as Enterprise AI Spending Accelerates in 2026
  9. [9]News articleYahoo Finance· April 26, 2026
    Fed Set to Lead Uneasy G-7 With Rates Kept on Hold This Week
  10. [10]Press releaseGlobeNewswire· April 20, 2026
    Spelman College Announces MS NOW Anchor and Political Strategist Symone Sanders Townsend as 139th Commencement Speaker
  11. [11]Press releaseGlobeNewswire· April 28, 2026
    UK Inventor Publishes Mathematical Framework for Disciplined Supply Creation Across Money, Credits, and Critical Resources. Introducing PDM and Mann Mechanics

In this story

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com